Selection from HEOR Bibliography

IMS logo
Search criteria
Condition: Comparative Effectiveness & Health Technology Assessment
 
Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions
Authors: Oriol Sola- Morales (1), Lesley H. Curtis (2), Julien Heidt (3),*, Laura Walsh (4), Deborah Casso (5),?, Susan Oliveria (6),?, Patrick Saunders- Hastings (7), Yufei Song (8),?, Tiffany Mercado (3), Robbert Zusterzeel (3),?, Vera Mastey (9), James Harnett (9) and Ruben G. W. Quek (9)
Affiliations: (1) Fundació Health Innovation Technology Transfer and International, University of Catalonia, Barcelona, Spain; (2) Duke Clinical Research Institute, Durham, North Carolina, USA; (3) IQVIA, Regulatory Science and Strategy, Falls Church, Virginia, USA; (4) IQVIA, Epidemiology and Drug Safety Practice, Boston, Massachusetts, USA; (5) IQVIA, Epidemiology and Drug Safety Practice, Seattle, Washington, USA; (6) IQVIA, Epidemiology and Drug Safety Practice, New York, New York, USA; (7) Epi Excellence LLC, Garnet Valley, Pennsylvania, USA; (8) IQVIA, Epidemiology and Drug Safety Practice, Beijing, China; (9) Regeneron Pharmaceuticals Inc., Health Economics & Outcomes Research, Tarrytown, New York, USA
Publications: 
Clinical pharmacology and therapeutics vol. 114,2 (2023): 325-355. doi:10.1002/cpt.2914
Document Types: , Article
Countries: , Europe, USA
Abstract: https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1002/cpt.2914
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment, Methodology, Regulatory 2023 English , Review
 
 
Regulatory and HTA Considerations for Development of Real- World Data Derived External Controls
Authors: Lesley H. Curtis (1), Oriol Sola-Morales (2), Julien Heidt (3),*, Patrick Saunders- Hastings (4), Laura Walsh (5), Deborah Casso (6),?, Susan Oliveria (7),?, Tiffany Mercado (3), Robbert Zusterzeel (3),?, Rachel E. Sobel (8), Jessica J. Jalbert (9), Vera Mastey (9), James Harnett (9) and Ruben G. W. Quek (9)
Affiliations: 1Duke Department of Population Health Sciences and Duke Clinical Research Institute, Durham, North Carolina, USA; 2Fundació HiTT and Universitat Internacional de Catalunya (UIC), Barcelona, Spain; 3IQVIA, Regulatory Science and Strategy, Falls Church, Virginia, USA; 4Epi Excellence LLC, Garnet Valley, Pennsylvania, USA; 5IQVIA, Epidemiology and Drug Safety Practice, Boston, Massachusetts, USA; 6IQVIA, Epidemiology and Drug Safety Practice, Seattle, Washington, USA; 7IQVIA, Epidemiology and Drug Safety Practice, New York, New York, USA; 8Regeneron Pharmaceuticals Inc., Pharmacoepidemiology, Tarrytown, New York, USA; 9Regeneron Pharmaceuticals Inc., Health Economics & Outcomes Research, Tarrytown, New York, USA.
Publications: 
Clin Pharmacol Ther, 114: 303-315. https://doi.org/10.1002/cpt.2913
Document Types: , Article
Countries: , USA
Abstract: https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1002/cpt.2913
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment, Methodology, Regulatory 2023 English , Review
 
 
The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis
Authors: Helmut Butzkueven, Jan Hillert, Merja Soilu-Hänninen, Tjalf Ziemssen, Jens Kuhle, Stig Wergeland, Melinda Magyari, Joseph R. Berger, Nicholas Moore, Aida Aydemir, Irene Bezemer & Meritxell Sabidó
Affiliations: "a Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia; b The Alfred Hospital, Melbourne, VIC, Australia; c Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; d Turku University Hospital Neurocenter and Division of Clinical Neurosciences, University of Turku, Turku, Finland; e Center of Clinical Neuroscience, Department of Neurology, Dresden University of Technology, Dresden, Germany; f Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland; g Department of Neurology, University Hospital and University of Basel, Basel, Switzerland; h Norwegian MS Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway; i Department of Clinical Medicine, University of Bergen, Bergen, Norway; j Danish Multiple Sclerosis Center and the Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; k Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; l Bordeaux PharmacoEpi (BPE), Universit�e de Bordeaux, Bordeaux, France; m EMD Serono Research & Development Institute, Inc, Billerica, MA, USA, an affiliate of Merck KGaA; n Global Epidemiology, IQVIA, Amsterdam, The Netherlands; o Merck Healthcare KGaA, Darmstadt, Germany"
Publications: 
Document Types: , Article
Countries: , Australia, Denmark, Finland, Germany, Norway, Sweden, Switzerland, Turkey
Abstract: https://www.tandfonline.com/doi/full/10.1080/03007995.2023.2256220
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment, Drug safety, Neurological disorders 2023 English , clinical setting: Secondary care, Epidemiological study, Population Based Study
 
 
The emerging role of real-world data in advanced breast cancer therapy: Recommendations for collaborative decision-making
Authors: Paul Cottu 1, Scott David Ramsey 2, Oriol Solà-Morales 3, Patricia A Spears 4, Lockwood Taylor 5
Affiliations: 1Department of Medical Oncology, Institut Curie, 26 Rue D'Ulm, 75005, Paris, France. Electronic address: paul.cottu@curie.fr. 2Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M2-B232, Seattle, WA, 98155, USA. Electronic address: sramsey@fredhutch.org. 3Health Innovation Technology Transfer Foundation, Aragó 60, E-08015, Barcelona, Spain. Electronic address: osola@fhitt.org. 48605 Carolingian Court, Raleigh, NC, 27615, USA. Electronic address: paspears88@gmail.com. 5Epidemiology, Real World Solutions at IQVIA, 4820 Emperor Boulevard, Durham, NC, 27703, USA. Electronic address: lockwood.taylor@iqvia.com.
Publications: 
Breast. 2021 Dec 22;61:118-122. doi: 10.1016/j.breast.2021.12.015.
Document Types: , Article
Countries: , France, Italy, USA
Abstract: https://pubmed.ncbi.nlm.nih.gov/34959093/
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment, Drug safety, Oncology, Regulatory 2022 English , Review
 
 
Evidence synthesis in pulmonary arterial hypertension: a systematic review and critical appraisal
Authors: Max Schlueter, Amélie Beaudet, Evan Davies, Binu Gurung, Andreas Karabis
Affiliations: IQVIA, 210 Pentonville Road, London, N1 9JY; IQVIA, Herikerbergweg 314, 1101 CT, Amsterdam, Netherlands; Department of Statistical Science, University College London, London, WC1E 6BT, UK.
Publications: 
Document Types: , Article
Countries: 
Abstract: https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-020-01241-4
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment, Methodology, Rare Diseases 2020 English , Literature Review, Review
 
 
Cost-utility model for 2nd generation treatment of chronic HCV in general population: impact of EASL recommendations in 2016 and 2018
Authors: Natlia Pascual-Argent (1,2); Carlos Crespo (1,3); Laura Planellas (4); Mriam Solozabal (4), Nria Perulero (4); Jaume Puig-Junoy (1,2)
Affiliations: (1) UPF Barcelona School of Management; (2) Dept. Economa y Empresa CRES UPF; (3) Universitat de Barcelona; (4) HEOR-RWE, IQVIA Spain
Publications: 
XXXIX Jornadas de Economa de la Salud. Albacete, 12 al 14 de junio de 2019
Document Types: , Poster
Countries: , Spain
Abstract: http://www.aes.es/jornadas/pdfs/Jornadas_AES_2019-Libro_abstracts.pdf
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment, Health economics, Infectious disease 2019 Spanish , Clinical setting: hospital, Cost effectiveness
 
 
Assessing the Outcomes for Orphan Status or Accelerated Assessment EMA Approved Medicines: A Comparison of Health Technology Assessment in Denmark, Finland, Norway and Sweden
Authors: Falla, Edel; Pitcher, Ashley; Acs, Annabel; Heller, Vincent; Zhang, Rongrong
Affiliations: IQVIA, Real-World Insights, London, LON, UK IQVIA, Real-World Insights, Copenhagen, Denmark IQVIA, Real-World Insights, Copenhagen, Denmark IQVIA, Real-World Insights, Solna, AB, Sweden IQVIA, Real-World Insights, Stockholm, Sweden
Publications: 
ISPOR Europe 2019, November 5, 2019, Copenhagen, Denmark
Document Types: , Poster
Countries: , Denmark, Finland, Nordic, Norway, Sweden
Abstract: https://www.valueinhealthjournal.com/article/S1098-3015(19)34089-6/fulltext?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301519340896%3Fshowall%3Dtrue#%20
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment 2019 English , Review
 
 
LIMITATIONS AND EXPECTED CHALLENGES OF CAR-T ECONOMIC EVALUATION.
Authors: Allou A*, Carette J*, Minacori R*, Touahmia S*, Bourguignon S*, Troubat A*, Maurel F*
Affiliations: IQVIA France - RWI
Publications: 
ISPOR 2018
Document Types: , Poster
Countries: , France
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment, Health economics, Hematology 2018 English , Cost effectiveness, Market impact, Review
 
 
WHAT INTERPRETATION OF ICERS IN ORPHAN DISEASES? A FRENCH EXAMPLE.
Authors: Moutier Hélène; Bourguignon Sandrine; Maurel Frédérique; Bodaghi Charles
Affiliations: RWI IQVIA France
Publications: 
ISPOR 2018
Document Types: , Poster
Countries: , France
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment, Health economics, Pricing and reimbursement, Rare Diseases 2018 English , Cost effectiveness, Pricing & Reimbursement, Willingness to pay
 
 
ASSESSMENT OF THE UNIT COSTS IN IMAGING ACTS: THE EXAMPLE OF MRI AND CT-SCAN ACTS IN France
Authors: Vasilescu L., Faller M., Allou A.
Affiliations: IQVIA France - RWI
Publications: 
ISPOR 2018
Document Types: , Poster
Countries: , France
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment, Methodology 2018 English , Literature Review, Public Health, Review
 
 
A COST-EFFECTIVENESS ANALYSIS COMPARING THE ORIGINATOR RECOMBINANT HUMAN ALFA TO THEIR BIOSIMILARS FOLLITROPIN ALFA FOR THE TREATMENT OF INFERTILITY.
Authors: Ravonimbola H(1), Petrica N (1), Maurel F(1), Murphy C(2), Doré C(2), Fresneau L(2),
Affiliations: (1) QuintilesIMS, Paris France (2) Merck Serono, France
Publications: 
ISPOR 2017
Document Types: , Poster
Countries: , France
Abstract: https://www.valueinhealthjournal.com/article/S1098-3015(17)31033-1/fulltext
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment 2017 English , Cost effectiveness, Literature Review, Randomised controlled trial
 
 
HEALTH-ECONOMICS EVALUATIONS IN FRANCE, ENGLAND, CANADA AND AUTRALIA: COMPARISON OF METHODOLOGIES AND IMPACT ON DRUGS
Authors: Bucher D*, Abalan M-E*, Allou A*, Dumon L*, Vialard L *, Troubat A*, Maurel F*
Affiliations: IQVIA France - RWI
Publications: 
ISPOR 2017
Document Types: , Poster
Countries: , Australia, Canada, France, UK
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment 2017 English , Cost effectiveness, Literature Review, Pricing & Reimbursement, Review
 
 
RiGOR: a prospective observational study comparing the effectiveness of treatment strategies for open-angle glaucoma.
Authors: Coleman AL1,2, Lum FC1, Velentgas P3, Campion D3, Su Z3, Gliklich RE4; RiGOR Study Group.
Affiliations: 1H. Dunbar Hoskins Jr, MD Center for Quality Eye Care, Foundation of the American Academy of Ophthalmology, 655 Beach Street, San Francisco, CA 94109, USA. 2Jules Stein Eye Institute, David Geffen School of Medicine & Fielding School of Public Health, University of California, Los Angeles, CA 90095, USA. 3Outcome DEcIDE Center, Quintiles Real World & Late Phase Research, Cambridge, MA 02139, USA.
Publications: 
Journal of Comparative Effectiveness. Jan 2016; 5(1), 65-78
Document Types: , Article
Countries: 
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26690903
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment 2016 English , Observational study, Prospective study, RWLPR (Real-World Late Phase Research-quintiles
 
 
Impact of treatment strategies for open angle glaucoma on intraocular pressure: the RiGOR study
Authors: Coleman AL1,2, Lum FC2, Velentgas P3, Su Z3, Gliklich RE4; RiGOR Study Group.
Affiliations: 1Jules Stein Eye Institute, David Geffen School of Medicine & Fielding School of Public Health, University of California, Los Angeles, CA 90095, USA. 2H Dunbar Hoskins, Jr MD Center for Quality Eye Care, Foundation of the American Academy of Ophthalmology, 655 Beach Street, San Francisco, CA 94109, USA. 3Outcome DEcIDE Center, Quintiles Real World & Late Phase Research, Cambridge, MA 02139, USA. 4Massachusetts Eye & Ear & Harvard Medical School, Boston, MA 02114, USA.
Publications: 
J Comp Eff Res. 2016 Jan;5(1):87-98
Document Types: , Article
Countries: 
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26691269
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment 2016 English , Observational study, Prospective study
 
 
Quality of life and visual acuity outcomes in the RiGOR study
Authors: Coleman AL1,2, Lum FC1, Gliklich RE3, Velentgas P4, Su Z4; RiGOR Study Group.
Affiliations: 1H Dunbar Hoskins, Jr MD Center for Quality Eye Care, Foundation of the American Academy of Ophthalmology, 655 Beach Street, San Francisco, CA 94109, USA. 2Jules Stein Eye Institute, David Geffen School of Medicine & Fielding School of Public Health, University of California, Los Angeles, CA 90095, USA. 3Massachusetts Eye & Ear Infirmary & Harvard Medical School, Boston, MA 02114, USA. 4Outcome DEcIDE Center, Quintiles Real World & Late Phase Research, 201 Broadway #5, Cambridge, MA 02139, USA.
Publications: 
J Comp Eff Res. 2016 Jan;5(1):99-111.
Document Types: , Article
Countries: 
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment 2016 English , Observational study, Prospective study
 
 
Practice patterns and treatment changes for open-angle glaucoma: the RiGOR study.
Authors: Coleman AL1,2, Lum FC2, Velentgas P3, Su Z3, Gliklich RE4; RiGOR Study Group.
Affiliations: 1Jules Stein Eye Institute, David Geffen School of Medicine & Fielding School of Public Health, University of California, Los Angeles, CA 90095, USA. 2H Dunbar Hoskins Jr, MD Center for Quality Eye Care, Foundation of the American Academy of Ophthalmology, 655 Beach Street, San Francisco, CA 94109, USA. 3Outcome DEcIDE Center, Quintiles Real World & Late Phase Research, Cambridge, MA, 02139. 4Massachusetts Eye & Ear Infirmary & Harvard Medical School, Boston, MA 02114, USA
Publications: 
J Comp Eff Res. 2016 Jan;5(1):79-85.
Document Types: , Article
Countries: 
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment 2016 English , Observational study, Prospective study
 
 
How market access will play out
Authors: Bosco j, Dreyer N
Affiliations: Quintiles Real World and late phase research
Publications: 
Managed healthcare executive
Document Types: 
Countries: 
Abstract: Managedhealthcareexecutive.com
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment 2016 English , RWLPR (Real-World Late Phase Research-quintiles
 
 
Comparative Effectiveness of Oxaliplatin Versus 5-flourouricil in Older Adults: An Instrumental Variable Analysis.
Authors: Mack CD1, Brookhart MA, Glynn RJ, Meyer AM, Carpenter WR, Sandler RS, Stürmer T.
Affiliations: Department of Epidemiology, UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC
Publications: 
Epidemiology. 2015 Sep;26(5):690-9.
Document Types: , Article
Countries: , USA
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment, Oncology 2015 English , Retrospective database analysis
 
 
Best Methods to Get Your Comparative Effectiveness Paper Cited: How GRACE Helps.
Authors: Dreyer NA, Bryant A, Velentgas P, Su Z.
Affiliations: Quintales real world and late phase research
Publications: 
Pharmacoepidemiol Drug Saf 2015; 24(S1):360
Document Types: , Abstract
Countries: 
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment 2015 English , Review, RWLPR (Real-World Late Phase Research-quintiles
 
 
Generating Real-world Safety and Effectiveness Evidence for Biosimilars: Current Issues and Methodological Considerations
Authors: Bosco JL, Dreyer NA, Neyarapally G, Brown JS.
Affiliations: Quintiles real world and late phase research
Publications: 
Pharmacoepidemiol Drug Saf 2015; 24(S1):416.
Document Types: , Abstract
Countries: 
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment 2015 English , Methodology, Review, RWLPR (Real-World Late Phase Research-quintiles
 
 
Comparing Three-way and Pairwise Propensity Score Matching Approaches for Analyses of a Real-world Comparative Effectiveness Study of Glaucoma Therapies (RiGOR).
Authors: Velentgas P, Bosco JLF, Franke KM, Coleman AL, Lum FC, Gliklich R, Park J, Su Z.
Affiliations: Quintiles real world and late phase research
Publications: 
Pharmacoepidemiol Drug Saf 2015; 24(S1):217
Document Types: , Abstract
Countries: 
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment 2015 English , Methodology, RWLPR (Real-World Late Phase Research-quintiles
 
 
Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study.
Authors: Emery P1, Gottenberg JE2, Rubbert-Roth A3, Sarzi-Puttini P4, Choquette D5, Taboada VM6, Barile-Fabris L7, Moots RJ8, Ostor A9, Andrianakos A10, Gemmen E11, Mpofu C12, Chung C13, Gylvin LH12, Finckh A14.
Affiliations: 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK. 2Department of Rheumatology, CHU Strasbourg, Strasbourg, France. 3University of Cologne, Cologne, Germany. 4L Sacco University Hospital, Milan, Italy. 5University of Montreal, Montreal, Canada. 6Facultad de Medicina, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Santander, Spain. 7Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México City, Mexico. 8Department of Rheumatology, University of Liverpool, Liverpool, UK. 9Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. 10Hellenic Foundation for Rheumatological Research, Athens, Greece. 11Quintiles, Rockville, Maryland, USA. 12F Hoffmann-La Roche Ltd, Basel, Switzerland. 13Genentech Inc, San Francisco, California, USA. 14University Hospital of Geneva, Geneva, Switzerland.
Publications: 
Ann Rheum Dis. 2015 Jun;74(6):979-84
Document Types: , Article
Countries: , Canada, Colombia, France, Germany, Greece, Italy, Mexico, Norway, Portugal, Spain, UK
Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431330/
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment, Rheumatology 2015 English , Clinical setting: hospital, clinical setting: Secondary care, Prospective study, RWLPR (Real-World Late Phase Research-quintiles
 
 
Cost-Effectiveness Analysis of Delayed-Release Dimethyl Fumarate for The Treatment of Relapsing Remitting Multiple Sclerosis In Spain.
Authors: Gasche D1, Restovic G1, Casado V2, Ramírez-Boix P3, Martínez Lopez J3
Affiliations: 1IMS Health, Barcelona, Spain; 2Mataro Hospital, Mataro, Barcelona, Spain; 3Biogen, Madrid, Spain
Publications: 
Value in Health. Volume 18, Issue 7, November 2015, Page A755
Document Types: , Abstract
Countries: , Spain
Abstract: https://www.sciencedirect.com/science/article/pii/S1098301515050123?via%3Dihub
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment, Health economics, Neurological disorders 2015 English , Clinical setting: hospital, Cost effectiveness, Literature Review
 
 
Comparative Effectiveness Research (CER) of Treatments for Advanced Melanoma in Europe Using Existing Real-World Data Sources: A Feasibility Assessment
Authors: Daumont MM, Juuti R, Hoeller C, Zagorska A, Mertano E, Korhonen P
Affiliations: Worldwide Health Economics & Outcomes Research, Bristol-Myers Squibb, Rueil-Malmaison, France
Publications: 
Pigment Cell & Melanoma Research (2015) 28 (6), pp. 753-826
Document Types: , Abstract
Countries: , Europe
Abstract: https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.12419
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment, Oncology 2015 English , Literature Review, Review
 
 
Use of the GRACE checklist for rating the quality of observational comparative effectiveness research
Authors: Dreyer NA, Bryant A, Su Z, Velentgas P.
Affiliations: Quintiles real world and late phase research
Publications: 
Value in Health Nov 2014; 7(17): A732
Document Types: , Abstract
Countries: 
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment 2014 English , Review, RWLPR (Real-World Late Phase Research-quintiles
 
 
Using real-world data for outcomes research and comparative effectiveness studies. Advantage Business Media
Authors: Mack C, Lang K.
Affiliations: Quintiles real world and late phase research
Publications: 
Drug Discovery & Development. Nov 2014
Document Types: , Article
Countries: 
Abstract: http://www.dddmag.com/article/2014/11/using-real-world-data-outcomes-research-and-comparative-effectiveness-studies
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment 2014 English , Review, RWLPR (Real-World Late Phase Research-quintiles
 
 
A framework for creating standardized outcome measures for patient registries.
Authors: Gliklich RE1, Leavy MB, Karl J, Campion DM, Levy D, Berliner E.
Affiliations: Quintiles Real World and late phase research
Publications: 
Journal Comparative Effectiveness Research. 2014 Sep;3(5):473-80
Document Types: , Article
Countries: 
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment 2014 English , RWLPR (Real-World Late Phase Research-quintiles
 
 
Guidelines and Recommendations for comparative effectiveness research methods
Authors: Noh E, Dreyer N, Ahn J
Affiliations: Quintiles Real World and late phase research
Publications: 
Pharmacoepidemiology Drug Safety
Document Types: , Abstract
Countries: 
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment 2014 English , RWLPR (Real-World Late Phase Research-quintiles
 
 
The GRACE checklist for rating the quality of observational studies of comparative effectiveness: a tale of hope and caution.
Authors: Dreyer NA1, Velentgas P, Westrich K, Dubois R.
Affiliations: Quintiles Real World and late phase research
Publications: 
J Manag Care Spec Pharm. 2014 Mar;20(3):301-8.
Document Types: , Article
Countries: 
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment 2014 English , RWLPR (Real-World Late Phase Research-quintiles
 
 
Developing a Protocol for Observational Comparative Effectiveness Research. A User’s Guide.
Authors: Velentgas P, Dreyer NA, Nourjah P, Smith SR, Torchia MM, eds.
Affiliations: 
Publications: 
AHRQ Publication No. 12(13)-EHC099. Rockville, MD: Agency for Healthcare Research and Quality. January 2013.
Document Types: , Book chapter
Countries: 
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment 2013 English , Review, RWLPR (Real-World Late Phase Research-quintiles
 
 
Using observational studies for comparative effectiveness: finding quality with GRACE.
Authors: Dreyer NA1.
Affiliations: Quintiles Real World and late phase research
Publications: 
J Comp Eff Res. 2013 Sep;2(5):413-8
Document Types: , Article
Countries: 
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment 2013 English , RWLPR (Real-World Late Phase Research-quintiles
 
 
Comparing propensity score estimation using logistic regression and generalized boosted regression in a real-world comparative effectiveness study of glaucoma therapies
Authors: Bosco JLF, Franke K, Coleman AL, Lum FC, Gliklich R, Su Z, Velentgas P
Affiliations: Quintiles Real World and Late phase research
Publications: 
29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, Canada, August 2013
Document Types: , Abstract
Countries: 
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment 2013 English , RWLPR (Real-World Late Phase Research-quintiles
 
 
Introducing the encepp working group (WG) on health technology assessment (HTA): Enhancing the generation of additional evidence for HTA processes
Authors: Sinclair, M., Lis, Y., Van Engen, A., Van Ganse, E., Autier, P., Daumer, M., Ehrenstein, V., Qizilbash, N., Méndez, I., Engel, P., Bergman, U., Fusco, D., Pasterk, M., Postma, M. J., Smulders, M., Van Staa, T., Pariente, A., Ruether, E., Toussi, M., Moore, N., Meyer, F. & Prieto, L
Affiliations: Quintiles real World and late phase research, IMS RWE
Publications: 
ISPOR 16th Annual European Congress, Dublin, Ireland, November 2013
Document Types: , Abstract
Countries: 
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment 2013 English , RWLPR (Real-World Late Phase Research-quintiles
 
 
There but for GRACE? A Validated Screening Tool for Quality Observational Studies of comparative effectiveness
Authors: Dreyer NA, Velentgas P, Westrich K, Dubois, RW
Affiliations: Quintiles Real World and late phase Research
Publications: 
Research on Methods, Databases & Management Methods Section Winner
Document Types: , Abstract
Countries: 
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment 2013 English , RWLPR (Real-World Late Phase Research-quintiles
 
 
Registry of Patient Registries (RoPR): Advancing Registries for Comparative Effectiveness Research.
Authors: Gliklich RE, Levy D, Campion DM, Leavy MB, Karl J, Berliner E, Khurana L, Hossfeld W.
Affiliations: Quintiles Real World and late phase research
Publications: 
29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
Document Types: , Abstract
Countries: 
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment 2013 English , RWLPR (Real-World Late Phase Research-quintiles
 
 
Registry of Patient Registries (RoPR): Supporting Registries for Comparative Effectiveness Research
Authors: Gliklich RE, Levy D, Campion DM, Leavy MB, Karl J, Berliner E, Khurana L, Hossfeld W
Affiliations: Quintiles Real World and late phase research
Publications: 
DIA 49th Annual Meeting, Boston, MA June 2013
Document Types: , Abstract
Countries: 
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment 2013 English , RWLPR (Real-World Late Phase Research-quintiles
 
 
Developing a Protocol for Observational Comparative Effectiveness Research. A User’s Guide
Authors: Velentgas P, Dreyer NA, Nourjah P, Smith SR, Torchia MM
Affiliations: Quintiles real World and late phase research
Publications: 
Agency for Healthcare Research and Quality.
Document Types: , Book chapter
Countries: 
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment 2013 English , RWLPR (Real-World Late Phase Research-quintiles
 
 
Prospective observational studies to assess comparative effectiveness
Authors: Berger, ML, Dreyer N, Anderson F, Towse A, Sedrakyan A,Normand SL
Affiliations: Quintiles real world and late phase research
Publications: 
Value in Health
Document Types: , Article
Countries: 
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment 2012 English , RWLPR (Real-World Late Phase Research-quintiles
 
 
Making observational studies count: shaping the future of comparative effectiveness research
Authors: Dreyer NA
Affiliations: Quintiles real world and late phase research
Publications: 
Epidemiology
Document Types: , Article
Countries: 
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment 2011 English , RWLPR (Real-World Late Phase Research-quintiles
 
 
Why observational studies should be among the tools used in comparative effectiveness research
Authors: Dreyer NA, Tunis S, Berger M, Ollendorf D, Mattox P, Gliklich RE
Affiliations: Quintiles real world and late phase research
Publications: 
Health Affairs
Document Types: , Article
Countries: 
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment 2010 English , RWLPR (Real-World Late Phase Research-quintiles
 
 
GRACE Initiative. GRACE principles: recognizing high-quality observational studies of comparative effectiveness
Authors: Dreyer NA, Schneeweiss S, McNeil BJ, Berger ML, Walker AM, Ollendorf DA, Gliklich RE
Affiliations: Quintiles real world and late phase research
Publications: 
Amer J Managed Care
Document Types: , Article
Countries: 
Condition Year Language Analysis type
, Comparative Effectiveness & Health Technology Assessment 2010 English , RWLPR (Real-World Late Phase Research-quintiles
 
 
Copyright 2024 IMS Health Incorporated. All rights reserved.